Awakn Life Sciences (AWKNF) Stock Price, News & Analysis

Company Overview

Awakn Life Sciences Inc. is a clinical-stage biotechnology company focused on the development and delivery of psychedelic-informed therapies for the treatment of addiction and other mental health disorders. The company’s research and development efforts center on novel formulations and delivery methods for compounds such as ibogaine and ketamine, aiming to create standardized, evidence-based protocols that can be adopted in clinical settings.

Awakn’s product pipeline includes proprietary drug development programs alongside therapy-led services delivered through specialized clinics. The company conducts preclinical research and oversees Phase 1 and Phase 2 clinical trials designed to evaluate safety, tolerability and efficacy. In parallel, Awakn has established treatment centers where patients can receive clinician-supervised, psychedelic-assisted therapy as part of integrated addiction treatment programs.

Founded in 2018 and headquartered in Cambridge, U.K., Awakn Life Sciences has built a network of research partnerships and clinical collaborations across Europe and North America. The company is led by a management team with backgrounds in neuroscience, clinical psychiatry and biotechnology development. Awakn is committed to advancing regulatory approval pathways and broadening patient access to next-generation therapies for substance use disorders.

Key Stats

• Today's Range: $0.07 to $0.07
• 50-Day Range: $0.07 to $0.07
• 52-Week Range: $0.05 to $0.19
• Volume: N/A
• Average Volume: 16,563 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:AWKNF
• CIK: N/A
• Web: awaknlifesciences.com
• Phone: N/A
• Fax: N/A
• Employees: 44
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A